|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that ethnicity or race should be given serious consideration when studying and interpreting S100b levels in persons with schizophrenia.
|
31786729 |
2020 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review addresses this novel scenario, presenting data indicating that S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease: acute brain injury (ischemic/hemorrhagic stroke, traumatic injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis), congenital/perinatal disorders (Down syndrome, spinocerebellar ataxia-1), psychiatric disorders (schizophrenia, mood disorders), inflammatory bowel disease.
|
30144068 |
2019 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aims to investigate whether the gene polymorphisms and haplotype of AQP4 are associated with serum S100 calcium-binding protein B (S100B) level and clinical symptoms in patients with schizophrenia (SCZ).
|
30618856 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls.
|
28435992 |
2018 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, GSK3B, HTR2A, PLA2G4A, and S100B variants may determine an anticipation of SCZ age of onset.
|
29164477 |
2018 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The levels of S100B, RAGE, and Fas Ligand of drug-naive first episode psychosis patients with schizophrenia were significantly higher than that of the same medicated first episode psychosis patients, indicating that an increase of apoptotic signaling is present at the onset of schizophrenia and is also associated with treatment progress.
|
29875007 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings support the hypothesis that glial dysfunction and associated marker protein S100B may contribute to the pathophysiologic development of neurocognitive deficits in the relapsed individuals with schizophrenia.
|
27863321 |
2017 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Animal studies have strongly implicated a role of S100B in spatial ability and our recent study of humans found that S100B gene polymorphisms (rs9722, rs1051169, and rs2839357) were associated with schizophrenia patients' spatial ability (as assessed by a block design task and a mental rotation task).
|
22019077 |
2012 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
The receptor for advanced glycation end products (RAGE) is the main receptor for S100B, an astrogial proinflammatory mediator that has been suggested to be involved in the pathophysiology of schizophrenia.
|
22146151 |
2012 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end products (RAGE) is the main receptor for S100B, an astrogial proinflammatory mediator that has been suggested to be involved in the pathophysiology of schizophrenia.
|
22146151 |
2012 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, associations were found between variations in the S100B gene and schizophrenia as well as bipolar affective disorder.
|
21112154 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Calcium-binding protein S100B has been implicated in the pathology of bipolar affective disorder (BPAD) and schizophrenia (SZ).
|
21714070 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
These results implicate a role for S100B gene polymorphisms in the cognitive functions of schizophrenia patients and encourage further investigation into spatial disability as an endophenotype of schizophrenia.
|
21070816 |
2011 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results implicate a role for S100B gene polymorphisms in the cognitive functions of schizophrenia patients and encourage further investigation into spatial disability as an endophenotype of schizophrenia.
|
21070816 |
2011 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These genes include GRM7, previously associated to major depression disorder and bipolar disorder, SLC6A13, in anxiety disorders, and S100B, SSTR5 and COMT in schizophrenia.
|
20398908 |
2010 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE.
|
19103440 |
2009 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The picture is not as clear regarding schizophrenia subtypes in acute states but patients with persistent negative symptoms or deficit syndrome show constant high S100B concentrations.
|
20093730 |
2009 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As indicated by increased levels of S100B, astrocytes are activated in schizophrenia.
|
17982903 |
2007 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Since variants within S100B have also been associated with schizophrenia susceptibility, we reanalyzed the data in trios with a history of psychosis, a phenotype in common between the two disorders.
|
17525977 |
2007 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Our finding of increased levels of S100B in patients with schizophrenia without an indication for significant glial (GFAP, MBP) or neuronal (NSE) damage may be interpreted as indirect evidence for increased active secretion of S100B during acute psychosis.
|
17043297 |
2006 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In schizophrenia, astrocytes in particular are activated, as increased levels of S100B appear.
|
17062375 |
2006 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
LHGDN |
Our results suggest that S100B could be a susceptible gene for schizophrenia and provide indirect evidence for the GGF/SD hypothesis.
|
15670788 |
2005 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that S100B could be a susceptible gene for schizophrenia and provide indirect evidence for the GGF/SD hypothesis.
|
15670788 |
2005 |